Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04814537 · ClinicalTrials.gov registry record · Phase 4

Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques

A Phase 4 study of Analgesia and Labor Pain, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT04814537: Completed Phase 4 study of Analgesia and Labor Pain, sponsored by Brigham and Women's Hospital.

NCT04814537 is a Phase 4 study of Analgesia and Labor Pain that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 100 participants, above the 88-participant average among 19 other Analgesia trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04814537, a Phase 4 study of Analgesia and Labor Pain, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

To estimate the dose of bupivacaine required to achieve initial effective comfort in 90% of patients (ED90) via the epidural (DPE or EPL) technique in women undergoing labor.

Primary Outcome

The dose of bupivacaine with which 90% of participants achieve adequate analgesia (NRS\<3 at 30min)

Conditions Studied

Interventions

  • DRUG Bupivacaine Hydrochloride

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-02-25
Est. Completion 2022-03-23
Phase Phase 4
Brigham and Women's Hospital

937 total trials

What the finished NCT04814537 record still lists

NCT04814537 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 19 other Analgesia trials with a reported enrollment target (14% higher).

The record links to 2 conditions, with Analgesia appearing as the primary indexed condition, and to 1 intervention - of which Bupivacaine Hydrochloride is the first listed.

NCT04814537 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04814537 about?

NCT04814537 is a clinical study titled "Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques". To estimate the dose of bupivacaine required to achieve initial effective comfort in 90% of patients (ED90) via the epidural (DPE or EPL) technique in women undergoing labor.

What is the current status of trial NCT04814537?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-02-25. Estimated completion is 2022-03-23.

What conditions does trial NCT04814537 study?

This clinical trial studies the following conditions: Analgesia, Labor Pain.

What interventions are being tested in trial NCT04814537?

The interventions under investigation include: Bupivacaine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT04814537?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04814537 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04814537's enrollment target sits among peer trials

100 7th of 19 higher than 10 of 19 other Analgesia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Analgesia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04814537, the US trial registry maintained by the National Library of Medicine. NCT04814537 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.